CAM Assay
Chorioallantoic Membrane Assay Angiogenesis and Biocompatibility · Also known as: chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model
The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The CAM assay is ideal for screening the angiogenic potential of biomaterial scaffolds, assessing whether a tissue-engineered construct will support vascularization in vivo, and evaluating pro- or anti-angiogenic drugs. It provides physiologically relevant results at a fraction of the cost and time of in vivo animal models (mouse or rat). However, the CAM assay is not suitable for studying systemic responses, testing immune-dependent phenomena, or assessing long-term (>14 day) outcomes due to the limited lifespan of the embryo. For comprehensive in vivo evaluation, the CAM assay serves as an excellent intermediate screening tool before mammalian implantation studies.
Strengths & limitations
- In vivo physiological microenvironment: the CAM provides genuine tissue context with living blood vessels, immune tolerance, and realistic vascular dynamics unavailable in 2D culture.
- Transparent and accessible: direct visualization and microscopic observation of neovascularization require no destructive dissection or staining, enabling serial observations.
- Rapid and quantitative: angiogenic response develops within 7–10 days, and vessel density can be measured objectively using image analysis.
- Cost-effective: chicken eggs are inexpensive and require minimal infrastructure compared to mammalian animal models.
- Ethically acceptable: embryonic tissues are not considered sentient, and the assay is performed before hatching, reducing animal welfare concerns.
- Avian versus mammalian differences: physiological and immunological differences between birds and mammals may limit translatability of results.
- Limited assay duration: the CAM model is practical only until embryonic day 17–18; longer-term outcomes cannot be assessed.
- Semiquantitative angiogenesis scoring: manual vessel counting or subjective density scoring introduces operator bias; image analysis methods improve but are not universal.
- No systemic outcome assessment: the CAM model does not permit evaluation of systemic inflammation, immune response, or distant organ effects.
Frequently asked
At what embryonic age should I apply my test material?
Most angiogenesis studies apply material on embryonic day 3 (E3) or E4 when the CAM is accessible and well-vascularized, but not so mature that new vessel formation is limited. E3 application allows 7–10 days of vascular response before the embryo becomes too large or vessels become senescent.
How do I prevent bacterial or fungal contamination of the egg after windowing?
Use strict aseptic technique: work near a flame, disinfect the egg surface with 70% ethanol before windowing, and use sterile instruments. Apply antibiotics to the window or implant area if appropriate for your application (though this may confound pro-angiogenic assessments). Incubate at 37°C with 60% humidity and inspect daily for mold or discoloration.
Can I implant my biomaterial directly on the CAM, or must I use a chamber?
Direct application to the CAM surface is acceptable and standard for most scaffolds and materials. Plastic rings or wells can be placed on the CAM to define the implant area and prevent material migration. Some protocols use small metal rings or grids to standardize implant geometry and facilitate imaging.
How do I quantify angiogenesis objectively?
Measure vessel density (vessels per unit area), branching points, or fractal dimension using image analysis software (e.g., Fiji, ImageJ, Imalytics). Alternatively, count primary vessel branches radiating from the material center, or estimate the area of neovascularization around the implant. Report all methods clearly for reproducibility.
What controls should I use in a CAM angiogenesis study?
Mandatory controls include a negative control (empty chamber or sham material showing baseline CAM vasculature) and a positive control (recombinant VEGF or FGF at a known pro-angiogenic dose). Including a matched biomaterial without growth factors isolates the material's intrinsic angiogenic potential from the effect of loaded bioactive agents.
Sources
- Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186. link ↗
- Ribatti, D. (2016). The chick embryo chorioallantoic membrane (CAM) assay. Current Protocols in Immunology, 15, 12.1-12.13. DOI: 10.1016/j.reprotox.2016.11.004 ↗
- Norris, C. S., Griffith, O. W., & Reid, L. M. (2003). The chorioallantoic membrane (CAM) as a model for angiogenesis. In Antiangiogenic Agents in Cancer Therapy. Humana Press, pp. 463-477. link ↗
How to cite this page
ScholarGate. (2026, June 3). Chorioallantoic Membrane Assay Angiogenesis and Biocompatibility. ScholarGate. https://scholargate.app/en/biomaterials/cam-assay
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Hemolysis AssayBiomaterials↔ compare
- Live/Dead AssayBiomaterials↔ compare
- Scratch Wound AssayBiomaterials↔ compare
- Transwell AssayBiomaterials↔ compare